Insulin Resistance in HIV-Patients: Causes and Consequences

Página do item simplificado
dc.contributor.authorPedro, Marcelo N.
dc.contributor.authorRocha, Guilherme Z.
dc.contributor.authorGuadagnini, Dioze
dc.contributor.authorSantos, Andrey
dc.contributor.authorMagro, Daniela O.
dc.contributor.authorAssalin, Heloisa B.
dc.contributor.authorOliveira, Alexandre G. [UNESP]
dc.contributor.authorPedro, Rogerio de Jesus
dc.contributor.authorSaad, Mario J. A.
dc.contributor.institutionUniversidade Estadual de Campinas (UNICAMP)
dc.contributor.institutionUniversidade Estadual Paulista (Unesp)
dc.date.accessioned2018-11-26T16:04:59Z
dc.date.available2018-11-26T16:04:59Z
dc.date.issued2018-09-05
dc.description.abstractHere we review how immune activation and insulin resistance contribute to the metabolic alterations observed in HIV-infected patients, and how these alterations increase the risk of developing CVD. The introduction and evolution of antiretroviral drugs over the past 25 years has completely changed the clinical prognosis of HIV-infected patients. The deaths of these individuals are now related to atherosclerotic CVDs, rather than from the viral infection itself. However, HIV infection, cART, and intestinal microbiota are associated with immune activation and insulin resistance, which can lead to the development of a variety of diseases and disorders, especially with regards to CVDs. The increase in LPS and proinflammatory cytokines circulating levels and intracellular mechanisms activate serine kinases, resulting in insulin receptor substrate-1 (IRS-1) serine phosphorylation and consequently a down regulation in insulin signaling. While lifestyle modifications and pharmaceutical interventions can be employed to treat these altered metabolic functions, the mechanisms involved in the development of these chronic complications remain largely unresolved. The elucidation and understanding of these mechanisms will give rise to new classes of drugs that will further improve the quality of life of HIV-infected patients, over the age of 50.en
dc.description.affiliationState Univ Campinas UNICAMP, Fac Med Sci, Dept Internal Med, Campinas, SP, Brazil
dc.description.affiliationState Univ Campinas UNICAMP, Fac Med Sci, Dept Surg, Campinas, SP, Brazil
dc.description.affiliationSao Paulo State Univ UNESP, Biosci Inst, Rio Claro, Brazil
dc.description.affiliationUnespSao Paulo State Univ UNESP, Biosci Inst, Rio Claro, Brazil
dc.description.sponsorshipFundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
dc.description.sponsorshipOCRC (Obesity and Comorbidities Research Center)
dc.description.sponsorshipINCT (National Institute of Science and Technology for Diabetes and Obesity)
dc.description.sponsorshipConselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)
dc.description.sponsorshipIdFAPESP: 201307607-8
dc.description.sponsorshipIdINCT (National Institute of Science and Technology for Diabetes and Obesity): 465693/2014-8
dc.format.extent10
dc.identifierhttp://dx.doi.org/10.3389/fendo.2018.00514
dc.identifier.citationFrontiers In Endocrinology. Lausanne: Frontiers Media Sa, v. 9, 10 p., 2018.
dc.identifier.doi10.3389/fendo.2018.00514
dc.identifier.fileWOS000443725600001.pdf
dc.identifier.issn1664-2392
dc.identifier.urihttp://hdl.handle.net/11449/160561
dc.identifier.wosWOS:000443725600001
dc.language.isoeng
dc.publisherFrontiers Media Sa
dc.relation.ispartofFrontiers In Endocrinology
dc.relation.ispartofsjr1,790
dc.rights.accessRightsAcesso aberto
dc.sourceWeb of Science
dc.subjectinsulin resistance
dc.subjectdiabetes
dc.subjectHIV
dc.subjectCVD
dc.subjectcART
dc.subjectLPS
dc.titleInsulin Resistance in HIV-Patients: Causes and Consequencesen
dc.typeResenha
dcterms.rightsHolderFrontiers Media Sa
unesp.author.lattes6249449004253286[7]
unesp.author.orcid0000-0002-6620-5477[7]

Arquivos

Pacote Original
Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
WOS000443725600001.pdf
Tamanho:
1006.18 KB
Formato:
Adobe Portable Document Format
Descrição:
Baixar

Coleções

Artigos